RapImmune®: How Intralymphatic Immunotherapy Works, and What the Research Shows

Living in Iowa means dealing with some of the Midwest's toughest allergy triggers. From the blooming tree pollen in spring that blankets Des Moines in a hazy cloud to the relentless grass pollen waves through summer and the ragweed explosion in fall, environmental allergies can turn your daily routine into a battle.

Add in year-round culprits like indoor mold from humid basements, dust mites hiding in bedding, and pet dander from your furry family members, and it's no wonder so many Iowans spend their days sneezing, rubbing itchy eyes, and popping antihistamines just to get through work or school. These aren't just annoyances—they disrupt sleep, sap productivity, and even strain relationships. Imagine missing family barbecues because of constant congestion or calling in sick because sinus pressure left you drained. An allergy-free lifestyle isn't a luxury; it's essential for thriving in our active Iowa communities, whether you're farming fields outside Ames or navigating office meetings downtown.

At Allergenix, we're changing the game with RapImmune®, our patented approach to intralymphatic immunotherapy (ILIT). As a board-certified allergist with over 15 years of experience and having endure five separate courses of immunotherapy in his lifetime. Dr. Stanga has seen first hand how traditional allergy shots fall short. That's why Allergenix is excited to introduce RapImmune® — a quick, effective treatment designed for busy Iowans who want lasting relief without the hassle.

What is Intralymphatic Immunotherapy (ILIT), and How Does RapImmune® Make It Better?

Intralymphatic immunotherapy is a cutting-edge form of allergen-specific immunotherapy (also known as allergy shots) that delivers allergy extracts directly into the lymph nodes, the body's immune command centers. Unlike traditional methods, ILIT bypasses the skin and bloodstream, targeting the root cause of allergies—your overactive immune response to environmental triggers like pollen, dust, mold, and pet dander—at lightning speed.

Here's how it works in simple terms: Under ultrasound guidance, a tiny dose of your personalized allergen extract is injected directly into an inguinal lymph node (in your groin area—quick and virtually painless). This direct delivery "trains" your immune system to tolerate allergens, reducing the reactions that cause symptoms.

The Science and History: A Proven Evolution

ILIT isn't new hype — it's rooted in decades of immunology research. The concept emerged in the early 2000s, building on subcutaneous immunotherapy (SCIT) pioneered in the 1910s. But the breakthrough came around 2008-2012 with Swiss and German trials demonstrating lymph node targeting could accelerate tolerance. By 2015, clinical trials confirmed its potential for allergic rhinitis.

Safety in published trials has been good, and the adverse events reported have been overwhelmingly local and mild. In a randomized trial of birch and grass pollen ILIT, local reactions occurred in 7.3 percent of actively treated patients against 2.7 percent on placebo (Ahlbeck et al., Clinical and Experimental Allergy 2023), and across seventeen trials 98.4 percent of all recorded adverse events were graded mild (Werner & Bosso, Allergy Asthma Proc 2021). Serious reactions are rare but not absent: a meta-analysis of 582 patients across 15 trials recorded two cases of anaphylaxis at a high allergen dose (Wang et al., Int Arch Allergy Immunol 2023). At Allergenix, every injection is ultrasound-guided, dosing is conservative, patients are observed afterward, and epinephrine is immediately available.

Across randomized trials, pooled analyses report a moderate reduction in combined symptom and medication scores compared with placebo — a standardized mean difference of −0.72 across the ten trials pooled for that outcome in one systematic review of seventeen studies (Werner & Bosso, Allergy Asthma Proc 2021) and −0.85 in another meta-analysis (Jiang et al., Mediators of Inflammation 2023) — alongside meaningful improvement in quality of life. Effect sizes of that magnitude are clinically meaningful, but they are not the same as a percentage of symptom improvement, and we would rather report what the studies actually measured than convert it into a number that sounds more precise than the evidence is.

What the evidence does not yet show

The research on ILIT is not unanimous, and anyone considering it should know that.

ILIT has been studied since 2008, when a team at the University Hospital Zurich published the first randomized trial showing that allergen delivered into a lymph node produced tolerance faster and with fewer injections than conventional therapy (Senti et al., PNAS 2008). The trials since then have not all agreed.

Set against that, Werner & Bosso 2021, Jiang et al. 2023 and Wang et al. 2023 all report significant benefit, and Wang found ILIT comparable to conventional allergy shots with a better safety profile.

1. Werner MT, et al. Intralymphatic immunotherapy for allergic rhinitis: A systematic review and meta-analysis. Allergy Asthma Proc. 2021 Jul 1;42(4):283-292. doi: 10.2500/aap.2021.42.210028. PMID: 34187620. A systematic review of seventeen trials. Across the ten pooled for that outcome it reports a standardized mean difference of −0.72 in combined symptom and medication scores against placebo, and records that 98.4 percent of all adverse events were graded mild.
2. Adlany YK, et al. Quality of life in allergic rhinitis patients treated with intralymphatic immunotherapy (ILIT): A 19-year follow-up. J Allergy Clin Immunol Glob. 2022 Oct 27;2(1):43-50. doi: 10.1016/j.jacig.2022.09.007. eCollection 2023 Feb. PMID: 37780115. A long-term follow-up of patients treated with ILIT, reporting sustained improvement in nasal and ocular symptoms and in quality of life.
3. Ahlbeck L, et al. Intralymphatic immunotherapy with birch and grass pollen extracts: A randomized double-blind placebo-controlled clinical trial. Clin Exp Allergy. 2023 Aug;53(8):862-873. doi: 10.1111/cea.14347. Epub 2023 Apr 4. PMID: 37013723. In this randomized controlled trial, two years after treatment, patients reported significantly fewer symptoms, lower medication use, and improved quality of life compared to placebo, with the treatment being safe and well-tolerated—no serious adverse events occurred.

RapImmune® elevates this with a proprietary protocol: allergen extracts, precise dosing, and follow-up tailored to Iowa's unique allergen profile (think high ragweed, grass, and mold levels). It's not for food allergies or venom — just those awful environmental ones that plague our state.

How RapImmune and Traditional Allergy Shots Compare

Traditional subcutaneous immunotherapy (SCIT)—those weekly "allergy shots" under the skin—has helped millions since the early 20th century. But let's be real: It demands shots 1-2 times per week, 3-6 months of buildup, with 50+ injections, then monthly boosters for 3-5 years. That's hundreds of clinic visits, 30 minute in-office monitoring for reactions (like hives or swelling in 10-20% of doses), and constant disruption to your life. For Iowa families juggling school runs and harvest seasons, it's exhausting.

1. Cox L et al. J Allergy Clin Immunol 2011;127:S1-55. PMID: 21122901
2. Senti G et al. Proc Natl Acad Sci USA 2008;105:17908-12 + multiple RCTs
3. AAAAI/ACAAI Practice Parameter 2011 – 30-min wait required
4. Tankersley MS et al. Ann Allergy Asthma Immunol 2000;85:251-5. PMID: 11035625 (16.3% local per injection)
5. Li Q et al. Allergy Asthma Proc 2020;41:282-7. PMID: 32605233 (0.095% systemic per injection)
6. Wang Y et al. J Asthma Allergy 2025;18:1-12. PMID: 38192845 (0.98% systemic per injection)
7. Wang Z et al. Medicine (Baltimore) 2024;103:e40579. PMID: 39560522 (meta-analysis, <5% AE, systemic ≈0%)
8. Durham SR et al. N Engl J Med 1999;341:468-75 (classic 70-80% sustained benefit)
9. Ahlbeck L et al. Clin Exp Allergy 2023;53:862-73. PMID: 37013723 (2-year RCT, comparable efficacy)

With RapImmune®, you're investing in freedom: Fewer sick days mean more productivity at your job or on the farm. Parents reclaim weekends with kids without allergy fog; athletes train without sniffles.

Tailored for Iowa

Across Iowa, where pollen counts spike to "extreme" levels in May (tree pollen) and September (ragweed), and winter molds thrive in our variable climate, untreated allergies take a real toll. RapImmune® targets these exact issues, helping you breathe easy at the Iowa State Fair or cozy up with your dog without watery eyes.